In vitro and in vivo antibacterial activities of TOC-50, a new parenteral cephalosporin, against enterococcus faecalis

Chemotherapy

Volumn 42, Issue 6, 1996, Pages 432-438

  Nomura, Shuichi ^a   Hanaki, Hideaki ^a   Furukawa, Tetsuo ^a   Unemi, Norio ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antibacterial activity; Enterococcus faecalis; TOC 50

Indexed keywords

AMIKACIN; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; HABEKACIN; IMIPENEM; MINOCYCLINE; OFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; TOC 50; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; ENTEROCOCCUS FAECALIS; EXPERIMENTAL INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029848912     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239476     Document Type: Article

References (11)

1. Murray B: The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65.
2. Eliopoulos GM: Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis 1993;12:409-412.
3. Johnson AP, Uttley AHC, Woodford N, George RC: Resistance to vancomycin and teicoplanin: An emerging clinical problem. Clin Microbiol Rev 1990;3:280-291.
4. Gordon S, Swenson JM, Hill BC: Antimicrobial susceptibility patterns of common and unusual species of cntcrococci causing infections in the United States. J Clin 1992;30:2373-2378.
5. Hanaki H, Akagi H, Shimizu C, Hyodo A, Uncmi N, Yasui M, Hara Y: Active new cephalosporin. TOC-39, TOC-50, against multi-resistant MRSA (abstract 889). Program and Abstracts 33th Intersci Conf Antimicrob Agents Chemother. New Orleans, 1993.
6. Finney DJ: Probit Analysis, ed 3. London, Cambridge University Press, 1971.
7. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(suppl 3B):72S-75S.
8. Sapico FL, Canawati HN, Ginunas VJ, Gilmore DS, Montgomery JZ, Tuddenham WJ, Facklam RR: En-terococci highly resistant to penicillin and ampicillin: An emerging clinical problem? J Clin Microbiol 1989;27:2091-2092.
9. Moellering RC: Emergence of cnte-rococcus as a significant pathogen. Clin Infect Dis 1992:14:1173-1178.
10. Arthur M, Courvalin P: Genetics and mechanism of glycopeptidc resistance in cntcrococci. Antimicrob Agents Chemothcr 1993:37:1563-1571.
11. Jones RN, Sader HS, Erwin ME. Anderson SC: Emerging multiply resistant cnterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis 1995:21:85-93.